WALTHAM,
Mass., Feb. 20, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that it will report its fourth
quarter and year-end 2023 financial results and provide a business
update on Tuesday, February 27, after
the close of the U.S. financial markets.
In connection with the earnings release, Syndax's management
will host a conference call and live audio webcast at 4:30 p.m. ET
on Tuesday, February 27, 2024 to
discuss the Company's financial results and provide a business
update.
The live audio webcast and accompanying slides may be accessed
through the Events & Presentations page in the Investors
section of the Company's website. Alternatively, the conference
call may be accessed through the following:
Conference ID: Syndax4Q23
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast:
https://www.veracast.com/webcasts/syndax/events/SNDX4Q23.cfm
For those unable to participate in the conference call or
webcast, a replay will be available on the Investors section of the
Company's website at www.syndax.com approximately 24 hours
after the conference call and will be available for 90 days
following the call.
About Syndax
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib, a highly selective inhibitor of the menin–KMT2A binding
interaction, and axatilimab, a monoclonal antibody that blocks the
colony stimulating factor 1 (CSF-1) receptor. For more information,
please visit www.syndax.com or follow the Company
on Twitter and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-to-announce-fourth-quarter-and-year-end-2023-financial-results-and-host-conference-call-and-webcast-on-february-27-2024-302066595.html
SOURCE Syndax Pharmaceuticals, Inc.